Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.
MDR-TB and HIV co-infection
Multidrug-resistant tuberculosis
Sub Saharan Africa
Treatment success
Unsuccessful treatment
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Aug 2019
16 Aug 2019
Historique:
received:
23
05
2019
accepted:
25
07
2019
entrez:
18
8
2019
pubmed:
20
8
2019
medline:
19
11
2019
Statut:
epublish
Résumé
Multidrug-resistant tuberculosis (MDR-TB) in HIV endemic settings is a major threat to public health. MDR-TB is a substantial and underreported problem in Sub-Saharan Africa (SSA), with recognised cases projected to increase with advancement in diagnostic technology. There is paucity of review evidence on treatment outcomes and antiretroviral (ART) uptake among MDR-TB patients with HIV in SSA. To address this gap a review of treatment outcomes in HIV patients co-infected with MDR-TB in the SSA region was undertaken. Three databases (Medline, Web of Science, CINHAL), Union on Lung Heath conference proceedings and grey literature were searched for publications between January 2004 and May 2018. Records were assessed for eligibility and data extracted. Random effect meta-analysis was conducted using STATA and Cochrane's review manager. A total of 271 publications were identified of which nine fulfilled the inclusion criteria. Data was collected from 3368 MDR-TB and HIV co-infected patients from four SSA countries; South Africa (6), Lesotho (1), Botswana (1) and Ethiopia (1). The most common outcome was cure (34.9% cured in the pooled analysis), this was followed by death (18.1% in pooled analysis). ART uptake was high, at 83% in the pooled analysis. Cure ranged from 28.6 to 54.7% among patients on ART and from 22.2 to 57.7% among those not on ART medication. MDR-TB and HIV co-infected patients were less likely to be successfully treated than HIV negative MDR-TB patients (Risk Ratio = 0.87, 95% CI 0.97, 0.96). Treatment outcomes for MDR-TB and HIV co-infected patients do not vary widely from those reported globally. However, treatment success was lower among HIV positive MDR-TB patients compared to HIV negative MDR-TB patients. Prompt antiretroviral initiation and interventions to improve treatment adherence are necessary.
Sections du résumé
BACKGROUND
BACKGROUND
Multidrug-resistant tuberculosis (MDR-TB) in HIV endemic settings is a major threat to public health. MDR-TB is a substantial and underreported problem in Sub-Saharan Africa (SSA), with recognised cases projected to increase with advancement in diagnostic technology. There is paucity of review evidence on treatment outcomes and antiretroviral (ART) uptake among MDR-TB patients with HIV in SSA. To address this gap a review of treatment outcomes in HIV patients co-infected with MDR-TB in the SSA region was undertaken.
METHODS
METHODS
Three databases (Medline, Web of Science, CINHAL), Union on Lung Heath conference proceedings and grey literature were searched for publications between January 2004 and May 2018. Records were assessed for eligibility and data extracted. Random effect meta-analysis was conducted using STATA and Cochrane's review manager.
RESULTS
RESULTS
A total of 271 publications were identified of which nine fulfilled the inclusion criteria. Data was collected from 3368 MDR-TB and HIV co-infected patients from four SSA countries; South Africa (6), Lesotho (1), Botswana (1) and Ethiopia (1). The most common outcome was cure (34.9% cured in the pooled analysis), this was followed by death (18.1% in pooled analysis). ART uptake was high, at 83% in the pooled analysis. Cure ranged from 28.6 to 54.7% among patients on ART and from 22.2 to 57.7% among those not on ART medication. MDR-TB and HIV co-infected patients were less likely to be successfully treated than HIV negative MDR-TB patients (Risk Ratio = 0.87, 95% CI 0.97, 0.96).
CONCLUSION
CONCLUSIONS
Treatment outcomes for MDR-TB and HIV co-infected patients do not vary widely from those reported globally. However, treatment success was lower among HIV positive MDR-TB patients compared to HIV negative MDR-TB patients. Prompt antiretroviral initiation and interventions to improve treatment adherence are necessary.
Identifiants
pubmed: 31420021
doi: 10.1186/s12879-019-4317-4
pii: 10.1186/s12879-019-4317-4
pmc: PMC6697933
doi:
Substances chimiques
Anti-HIV Agents
0
Antitubercular Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
723Subventions
Organisme : Medical Research Council
ID : MC_PC_MR/R024278/1
Pays : United Kingdom
Références
Int J Tuberc Lung Dis. 2005 Jun;9(6):640-5
pubmed: 15971391
Thorax. 2006 Feb;61(2):158-63
pubmed: 16254056
J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-107
pubmed: 17624830
Int J Tuberc Lung Dis. 2010 Apr;14(4):420-6
pubmed: 20202299
PLoS One. 2012;7(10):e46943
pubmed: 23115633
S Afr Med J. 2013 Feb 26;103(4):229-31
pubmed: 23547697
PLoS One. 2014 Jan 08;9(1):e82235
pubmed: 24416139
Int J Tuberc Lung Dis. 2014 Feb;18(2):147-54
pubmed: 24429305
BMC Infect Dis. 2014 Jun 17;14:333
pubmed: 24938738
PLoS One. 2014 Nov 12;9(11):e112017
pubmed: 25391135
Lancet Respir Med. 2015 Mar;3(3):220-34
pubmed: 25773212
Trans R Soc Trop Med Hyg. 2015 May;109(5):340-8
pubmed: 25787727
BMC Public Health. 2015 Mar 25;15:291
pubmed: 25880829
HIV Med. 2015 Oct;16(9):544-52
pubmed: 25959854
Int J Tuberc Lung Dis. 2015 Aug;19(8):969-78
pubmed: 26162364
Thorax. 2015 Dec;70(12):1181-8
pubmed: 26506854
BMC Infect Dis. 2015 Oct 28;15:478
pubmed: 26511616
PLoS One. 2015 Dec 30;10(12):e0145380
pubmed: 26716686
PLoS One. 2016 Mar 07;11(3):e0144249
pubmed: 26950554
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):65-71
pubmed: 27552155
BMC Med. 2016 Nov 3;14(1):160
pubmed: 27806714
BMC Infect Dis. 2017 Feb 7;17(1):129
pubmed: 28173763
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596434
J Infect. 2018 Jan;76(1):44-54
pubmed: 29061336
Clin Infect Dis. 2018 Apr 3;66(8):1246-1253
pubmed: 29293906
Sci Rep. 2018 Mar 21;8(1):4980
pubmed: 29563561